4CPS-019 Evaluation of venous thromboembolic event prophylaxis in hospitalised cancer patients: a single-centred retrospective study

BackgroundVenous thromboembolic events are one of the main causes of death in cancer patients. Therefore, attempts have been made to prevent these events and reduce substantial burden on patient health.PurposeThis study aimed to evaluate the appropriateness of thromboprophylaxis in hospitalised canc...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2018-03, Vol.25 (Suppl 1), p.A49-A50
Main Authors: Mohammadi, M, Ebrahimpour, S, Jahangard-Rafsanjani, Z
Format: Article
Language:English
Subjects:
Cancer
Disease prevention
Health risk assessment
Section 4: Clinical pharmacy services
Thromboembolism
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundVenous thromboembolic events are one of the main causes of death in cancer patients. Therefore, attempts have been made to prevent these events and reduce substantial burden on patient health.PurposeThis study aimed to evaluate the appropriateness of thromboprophylaxis in hospitalised cancer patients.Material and methodsMedical records of 196 cancer patients hospitalised in two oncology wards of a tertiary care teaching hospital were investigated retrospectively. Appropriateness of thromboprophylaxis was determined using a local protocol prepared based on international guidelines.ResultsForty-seven out of 196 prescriptions (23.5%) were appropriate according the local protocol. About 76% (149/196) of patients did not have any acute medical illness or risk factors for thromboembolism and were admitted only to receive short-course chemotherapy. Enoxaparin was the drug used for 194 patients and unfractionated heparin was used for only two patients. Dose adjustment was not performed in three patients who needed dose modification with respect to renal impairment or obesity.ConclusionThis study has found that the frequency of thromboprophylaxis was considerably high in the study population. In the absence of an acute medical illness or other risk factors, hospitalisation per se does not justify administration of pharmacologic agents for thromboembolism prophylaxis. Implementation of local protocols prepared based on international guidelines seems necessary to rationalise thromboprophylaxis.References and/or AcknowledgementsWe gratefully appreciate Dr Soha Namazi for her expert advice.No conflict of interest
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2018-eahpconf.110